An Observational Study of the Application of a Topical Cannabinoid Gel on Sensitive Dry Skin

Maghfour, Jalal; Rietcheck, Hope R; Rundle, Chandler W.; Runion, Taylor M; Jafri, Zainab A; Dercon, Sam; Lio, Peter; Fernandez, Jon; Fujita, Mayumi; Dellavalle, Robert P.; Yardley, Helena

doi:10.36849/jdd.2020.5464

Cited by 18 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Maghfour and colleagues, researchers investigated the efficacy of topicsal CBD in the treatment of inflammatory skin disorders such as eczema [278]. Using the Patient Oriented Eczema Measure (POEM) and the Quality-of-Life Hand Eczema Questionnaire (QOLHEQ), subjects self-reported a significant reduction in eczema severity, reduction in the psychosocial burden of eczema, reduction in the emotional burden of eczema, decreased itching, and overall improvement of eczema [278].…”

Section: Eczemamentioning

confidence: 99%

The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases

Lowe

Toyang²,

Steele

et al. 2021

IJMS

163

View full text Add to dashboard Cite

The Endocannabinoid System (ECS) is primarily responsible for maintaining homeostasis, a balance in internal environment (temperature, mood, and immune system) and energy input and output in living, biological systems. In addition to regulating physiological processes, the ECS directly influences anxiety, feeding behaviour/appetite, emotional behaviour, depression, nervous functions, neurogenesis, neuroprotection, reward, cognition, learning, memory, pain sensation, fertility, pregnancy, and pre-and post-natal development. The ECS is also involved in several pathophysiological diseases such as cancer, cardiovascular diseases, and neurodegenerative diseases. In recent years, genetic and pharmacological manipulation of the ECS has gained significant interest in medicine, research, and drug discovery and development. The distribution of the components of the ECS system throughout the body, and the physiological/pathophysiological role of the ECS-signalling pathways in many diseases, all offer promising opportunities for the development of novel cannabinergic, cannabimimetic, and cannabinoid-based therapeutic drugs that genetically or pharmacologically modulate the ECS via inhibition of metabolic pathways and/or agonism or antagonism of the receptors of the ECS. This modulation results in the differential expression/activity of the components of the ECS that may be beneficial in the treatment of a number of diseases. This manuscript in-depth review will investigate the potential of the ECS in the treatment of various diseases, and to put forth the suggestion that many of these secondary metabolites of Cannabis sativa L. (hereafter referred to as “C. sativa L.” or “medical cannabis”), may also have potential as lead compounds in the development of cannabinoid-based pharmaceuticals for a variety of diseases.

show abstract

Section: Eczemamentioning

confidence: 99%

The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases

Lowe

Toyang²,

Steele

et al. 2021

IJMS

163

View full text Add to dashboard Cite

show abstract

“…There was an improvement in trans-epidermal water loss (TEWL) (p<0.001), and Psoriasis Area Severity Index (PASI) score (p <0.001), after a treatment period of three months (Palmieri et al, 2019), and in the Patient Oriented Eczema Measure (POEM) score from 16 to 8.1 (p <0.007) (Maghfour et al, 2020) at two weeks. In the same study (Maghfour et al, 2020), in which authors assessed the emotional burden of AD using the Quality of Life Hand Eczema Questionnaire (QOLHEQ), a significant reduction in the emotional domain of QOLHEQ was noted following treatment completion (20.9±2.06 vs 8.37 ±1.609 P<0.004) Topical Adelmidrol, an analogue of PEA, appeared effective for the treatment of pediatric AD (Pulvirenti et al, 2007). Following a treatment course of four weeks, all participants experienced a significant improvement in pruritus and erythema; 16 (80%) experienced clinical resolution.…”

Section: Atopic Dermatitismentioning

confidence: 99%

“… Pruritus, burning, and erythema Pulvirenti et al. 2007 3 Cohort study, n = 20 Topical adelmidrol 16 (80%) experienced complete resolution of AD symptoms AEs not reported Maghfour et al. 2020 ) 3 Cohort study, n = 16 Topical CBD, b.i.d.…”

Section: Mechanistic Action Of Oral Cbsmentioning

confidence: 99%

“…After duplicates were removed, two reviewers (TES and JM) independently screened articles on the basis of title, abstract, and full-text review to determine eligibility. One article ( Maghfour et al., 2020 ) known to the authors from previous research was also included, with 26 reports eligible for inclusion in this review. Of these, 12 were clinical trials (randomized, open label); six were cohort studies, including one retrospective study; six were case reports or case series; and two were pilot studies.…”

Section: Mechanistic Action Of Oral Cbsmentioning

confidence: 99%

“…The efficacy of topical CBs for dermatitis treatment was reported six times ( Cocchiara et al., 2019 ; Eberlein et al., 2008 ; Maghfour et al., 2020 ; Palmieri et al., 2019 ; Pulvirenti et al., 2007 ; Yuan et al., 2014 ). A total of 60 female participants with asteatotic eczema experienced an improvement in scaling, dryness, and itch ( P < 0.05) after the use of topical N-PEA and AEA ( Yuan et al., 2014 ).…”

Section: Efficacy Of Topical Cbsmentioning

confidence: 99%

See 2 more Smart Citations

Cannabinoids for the Treatment of Dermatologic Conditions

et al. 2022

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Novel Topical Treatments for Itch

Mahmoud,

Biazus Soares

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

The experience of itch often poses a burden on patient quality of life and has the capacity to inflict significant suffering. Topical therapies are a mainstay of treatment for many cutaneous and systemic diseases and afford patients the opportunity to manage their conditions without many of the systemic side effects of non-topical therapies. We review a multitude of new topical medications targeting the skin, immune system, and neural receptors. The list includes Janus kinase inhibitors, tyrosine kinase inhibitors, phosphodiesterase inhibitors, transient receptor vanilloid inhibitors, topical cannabinoids, and topical acetaminophen. Many of the topical therapies reviewed show promising data in phase 2–3 clinical trials, but further research is needed to compare therapies head-to-head and test their efficacy on a broader range of conditions.

show abstract

An Observational Study of the Application of a Topical Cannabinoid Gel on Sensitive Dry Skin

Cited by 18 publications

References 0 publications

The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases

The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases

Cannabinoids for the Treatment of Dermatologic Conditions

Novel Topical Treatments for Itch

Contact Info

Product

Resources

About